EHA

Kura files $100m offer after menin inhibitor results in AML
Kura files $100m offer after menin inhibitor results in AML
Pharmaphorum
Kura Oncology
ziftomenib
AML
stock offering
EHA
Flag link:
EHA 2023 – Astrazeneca keeps up its complement defense
EHA 2023 – Astrazeneca keeps up its complement defense
EP Vantage
EHA
AstraZeneca
Alexion
Soliris
Ultomiris
Novartis
iptacopan
PNH
Flag link:
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track
Pharmaforum
Daiichi Sankyo
EHA
quizartinib
clinical trials
acute myeloid leukemia
Flag link:
Cogent Soars on Positive Mid-Stage Data in Rare Blood Disorder
Cogent Soars on Positive Mid-Stage Data in Rare Blood Disorder
BioSpace
EHA
Cogent Biosciences
clinical trials
bezuclastinib
AdvSM
Flag link:
The hangover: Caribou's allogeneic CAR-T hit by durability doubts as half of patients relapse
The hangover: Caribou's allogeneic CAR-T hit by durability doubts as half of patients relapse
Fierce Biotech
Caribou Biosciences
CRISPR
CAR-T
allogenic CAR-T
EHA
non-Hodgkin's lymphoma
Flag link:
EHA 2022 preview – some good news at last
EHA 2022 preview – some good news at last
EP Vantage
EHA
Caribou Biosciences
CB-010
Gracell
Autolus
Roche
Curocell
ADC Therapeutics
Mustang Bio
Flag link:
CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise
CRISPR Therapeutics’ CAR-T for Lymphoma Shows Early Promise
BioSpace
CRISPR Therapeutics
CTX130
clinical trials
lymphoma
EHA
Flag link:
EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice
EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice
Fierce Biotech
EHA
Epizyme
Multiple Myeloma
EPZ-719
Flag link:
EHA: Johnson & Johnson, nearing Sanofi showdown, bolsters Darzalex's myeloma lead with 'unprecedented' survival data
EHA: Johnson & Johnson, nearing Sanofi showdown, bolsters Darzalex's myeloma lead with 'unprecedented' survival data
Fierce Pharma
JNJ
Darzalex
Multiple Myeloma
Sanofi
Sarclisa
EHA
Flag link:
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
Pharmaforum
Novartis
iptacopan
clinical trials
PNH
EHA
Flag link:
EHA 2021 – Curis’s renaissance continues
EHA 2021 – Curis’s renaissance continues
EP Vantage
Curis
CA-4948
EHA
myelodysplastic syndrome
acute myelogenous leukemia
clinical trials
Flag link:
With Sanofi entering the multiple myeloma market, J&J flashes data on new rare disease
With Sanofi entering the multiple myeloma market, J&J flashes data on new rare disease
Endpoints
EHA
JNJ
clinical trials
Darzalex
AL amyloidosis
Flag link:
EHA: AbbVie, Roche cement Venclexta's place in AML with survival win
EHA: AbbVie, Roche cement Venclexta's place in AML with survival win
Fierce Pharma
AbbVie
Roche
Venclexta
AML
EHA
Flag link:
EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win
EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win
Fierce Pharma
light chain amyloidosis
JNJ
Darzalex
EHA
Flag link:
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
BioPharma Dive
CRISPR
gene therapy
beta thalassemia
sickle cell disease
CRISPR Therapeutics
Vertex
Bluebird Bio
EHA
Flag link:
Cancer drugmaker Agios offers promising data from two studies testing blood disorder drug
Cancer drugmaker Agios offers promising data from two studies testing blood disorder drug
Endpoints
EHA
Agios
mitapivat
thalassemia
Flag link:
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EP Vantage
Bluebird Bio
sickle cell disease
LentiGlobin
EHA
Flag link:
Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent
Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent
BioSpace
Imago
clinical trials
EHA
myelofibrosis
bomedemstat
Flag link:
EHA 2019 – turnaround puts Arqule in the takeover frame
EHA 2019 – turnaround puts Arqule in the takeover frame
EP Vantage
Arqule
ARQ 531
EHA
Btk inhibitors
Flag link: